Tiziana Life Sciences (Nasdaq:TLSA) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

TLSA Stoklara Genel Bakış

Bir biyoteknoloji şirketi olan Tiziana Life Sciences Ltd, Amerika Birleşik Devletleri'nde onkoloji ve immünoloji alanlarında insan hastalıklarını tedavi edecek moleküllerin keşfi ve geliştirilmesine odaklanmaktadır.

Şirket hakkında

TLSA temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Kazançlar son 5 yılda yılda 12.3% oranında azaldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Anlamlı bir piyasa değeri yok ( $97M )

Tiziana Life Sciences Ltd Rakipler

Anixa Biosciences

NasdaqCM:ANIX

US$101.4m

Coya Therapeutics

NasdaqCM:COYA

US$104.0m

Lirum Therapeutics

NasdaqCM:LRTX

US$102.0m

Leap Therapeutics

NasdaqCM:LPTX

US$94.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Tiziana Life Sciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.00
52 Haftanın En Yüksek Seviyesi	US$1.74
52 Haftanın En Düşük Seviyesi	US$0.41
Beta	0.18
11 Aylık Değişim	8.70%
3 Aylık Değişim	20.48%
1 Yıllık Değişim	37.93%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-33.33%

Son Haberler & Güncellemeler

Recent updates

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct 12

Tiziana chief medical officer further increases holdings in company

Sep 23

Tiziana Life Sciences executive chairman further raises stake in company

Sep 16

Tiziana executive chairman raises stake in company again, buys more shares

Aug 25

Tiziana Life Sciences discloses share purchase by executive chairman

Aug 17

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Aug 15

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Jul 15

Hissedar Getirileri

	TLSA	US Biotechs	US Pazar
7D	-1.0%	-0.5%	0.3%
1Y	37.9%	18.0%	32.4%

Getiri vs. Endüstri: TLSA geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: TLSA geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is TLSA's price volatile compared to industry and market?
TLSA volatility
TLSA Average Weekly Movement	16.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: TLSA hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: TLSA 'nin haftalık oynaklığı ( 16% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1998	9	Gabriele Marco Cerrone	www.tizianalifesciences.com

Bir biyoteknoloji şirketi olan Tiziana Life Sciences Ltd, Amerika Birleşik Devletleri'nde onkoloji ve immünoloji alanlarında insan hastalıklarını tedavi etmek için moleküllerin keşfi ve geliştirilmesine odaklanmaktadır. Şirketin immünoloji alanındaki lider ürün adayı, Crohn, graft versus host, ülseratif kolit, multipl skleroz, tip-1 diyabet, inflamatuar bağırsak, sedef hastalığı ve romatoid artrit hastalıklarının tedavisi için bir insan anti-CD3 monoklonal antikoru (mAb) olan Foralumab'dır (TZLS-401). Ayrıca, çeşitli siklin bağımlı kinazların ve Src ailesinin oral yoldan biyoyararlanabilen küçük moleküllü geniş spektrumlu bir inhibitörü olan Milciclib'i (TZLS-201) ve enflamatuar ve onkoloji endikasyonlarının tedavisi için IL-6 reseptörünü hedefleyen tam insan mAb olan TZLS-501'i geliştirmektedir.

Tiziana Life Sciences Ltd Temel Bilgiler Özeti

Tiziana Life Sciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TLSA temel i̇stati̇sti̇kler
Piyasa değeri	US$99.87m
Kazançlar(TTM)	-US$17.69m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-5.7x

F/K Oranı

TLSA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TLSA gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$17.69m
Kazançlar	-US$17.69m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.17
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

TLSA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

TLSA Stoklara Genel Bakış

Ödüller

Risk Analizi

Tiziana Life Sciences Ltd Rakipler

NasdaqCM:ANIX

US$101.4m

NasdaqCM:COYA

US$104.0m

NasdaqCM:LRTX

US$102.0m

NasdaqCM:LPTX

US$94.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Insufficient new directors

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program

Recent updates

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Insufficient new directors

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program

Tiziana Life Sciences Ltd announced delayed 20-F filing

Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology

New minor risk - Share price stability

Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis

New minor risk - Financial data availability

Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment

Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)

Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

New major risk - Share price stability

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study

Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022

Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects

Less than half of directors are independent

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns)

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana chief medical officer further increases holdings in company

Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index

Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences discloses share purchase by executive chairman

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer

Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences Receives Nasdaq Deficiency Notice

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules